Alan Carr

Elon Musk's proposed acquisition of Twitter, Inc. (NASDAQ: TSLA) may have one less opposition to contend with, going by a statement released by one of the commissioners of the Federal Communications Commission. FCC Commissioner Alan Carr, a Republican by political affiliation, said...

Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine candidate, mRNA-1273, got FDA panel backing, in line with expectations, and is likely to be accorded emergency use authorization any time now. An Unsurprising Decision: The 20-0 vote, with one abstention, in favor of issuing an EUA for mRNA-1273...

Moderna Inc (NASDAQ: MRNA) has been one of the best performing stocks of 2020 thanks to its COVID-19 vaccine development program. A Needham analyst stepped to the sidelines Wednesday due to the heady valuation. The Moderna Analyst: Alan Carr downgraded Moderna shares from Buy to Hold and...

Moderna Inc (NASDAQ: MRNA) announced Monday positive efficacy data from the first interim analysis of the Phase 3 COVE study of its investigational coronavirus vaccine mRNA-1273. The Moderna Analysts: SVB Leerink analyst Mani Foroohar maintained an Underperform rating on Moderna. Needham analyst...

Moderna Inc (NASDAQ: MRNA) reported mixed quarterly results Thursday and suggested an interim efficacy readout from the Phase 3 study is likely in November. The Moderna Bull Case: Moderna's vaccine timeline is intact, according to Needham analyst Alan Carr, who rates the shares a Buy...

Biopharma stocks are risky bets that could fetch disproportionate gains or wipe away one's entire investment thanks to their vulnerability to catalytic events. The iShares Nasdaq Biotechnology Etf (NASDAQ: IBB) has gained about 20% year-to-date period compared to the roughly 9.3% advance by the...

Even as major pharma companies face hiccups in their coronavirus vaccine programs, Moderna Inc (NASDAQ: MRNA) is slowly and steadily progressing in its quest to obtain emergency use authorization for its vaccine candidate mRNA-1273 before the year is out.  The Moderna Analyst...

Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) held a virtual R&D event Thursday, showcasing its portfolio and key therapeutic areas. The Moderna Analysts: Chardan analyst Geulah Livshits has a Buy rating on Moderna with a $95 price target.  SVB Leerink analyst Mani...

Gilead Sciences, Inc. (NASDAQ: GILD) reported second-quarter revenues and earnings that trailed expectations. The Gilead Analysts Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and $79 price target for Gilead. Raymond James analyst Steven Seedhouse maintained a Market...

Cara Therapeutics Inc (NASDAQ: CARA) stock spiked 34 percent Wednesday after the company reported that a Phase 2/3 trial for intravenous CR845 met primary and secondary endpoints. The investor bullishness resonated with Needham.  The Rating Needham analyst Alan Carr maintained a...

Needham upgraded shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) from Hold to Buy, with a price target of $155. The price target, according to the firm, is based on 25 times its estimated earnings per share for 2022, discounted 20 percent annually. Analysts Alan Carr and Danielle...